Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 9,025 shares, a drop of 31.5% from the January 29th total of 13,176 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 49,744 shares, the short-interest ratio is currently 0.2 days. Based on an average daily trading volume, of 49,744 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the company are short sold.

Fresenius SE & Co. Stock Down 0.7%

FSNUY stock opened at $15.10 on Monday. The business’s 50-day moving average price is $14.60 and its 200-day moving average price is $14.43. The stock has a market cap of $34.02 billion, a P/E ratio of 23.97 and a beta of 0.75. The company has a quick ratio of 0.99, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Fresenius SE & Co. has a twelve month low of $9.78 and a twelve month high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its earnings results on Wednesday, February 25th. The company reported $0.28 earnings per share (EPS) for the quarter. Fresenius SE & Co. had a net margin of 5.71% and a return on equity of 10.38%. The company had revenue of $6.94 billion during the quarter. On average, equities research analysts forecast that Fresenius SE & Co. will post 0.79 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Monday, December 15th. Citigroup reiterated a “buy” rating on shares of Fresenius SE & Co. in a research note on Tuesday, February 3rd. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Fresenius SE & Co. has an average rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.